Reid E, Suneja G, Alexiev B, Ard K, Baiocchi R, Campbell T, Carchman E, Cohen S, Dickson MA, Eschenauer G, Goyal G, Grilley-Olson J, Gupta A, Henry DH, Hicks D, Jones A, Klopp A, Korpics M, LaCasce AS, Lee T, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Park HS, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Vogt S, Wang CJ, Freedman-Cass D, Nguyen J, Sansone N, Schonfeld R. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kaposi Sarcoma , National Comprehensive Cancer Network: 2025
Reid E, Suneja G, Alexiev B, Ard K, Baiocchi R, Campbell T, Carchman E, Cohen S, Dickson MA, Eschenauer G, Goyal G, Grilley-Olson J, Gupta A, Henry DH, Hicks D, Jones A, Klopp A, Korpics M, LaCasce AS, Lee T, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Park HS, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Vogt S, Wang CJ, Freedman-Cass D, Sansone N, Schonfeld R. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer in People with HIV , National Comprehensive Cancer Network: 2025
Evani Patel, Parisa Wootton, Clare Connolly, Patricia A. Locantore-Ford, Fumei Cerecino, Rebecca Pesce-Noga, David H. Henry Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds , Blood, 144 (Supplement 1): 2024
Emily Tomasulo, Sailaja Vinnakota, Michael Auerbach, David H. Henry, Patricia A. Locantore-Ford Optimization of Iron Deficiency Screening, Diagnosis, and Treatment in Pregnancy , Blood, 144 (Supplement 1): 2024
Evani Patel, Parisa Wootton, Clare Connolly, Patricia A. Locantore-Ford, Fumei Cerecino, Rebecca Pesce-Noga, David H. Henry Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can Be Safely Conducted At Lower Hemoglobin Thresholds , International Journal of Cancer Care and Delivery: 2024
Mittelman M, Henry DH, Glaspy JA, Tombak A, Harrup R, Kim I, Mądry K, Grabowska B, Lee T, Modelska K. Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial , Am J Hematol., 99(9): 2024,1778-1789
David Henry ASCO 2024: Abstract Recommendations From Dr. David Henry , PracticeUpdates: 2024
Gina Nicholson 1, Katherine B Carlson 2, Rohini K Hernandez 2, Jennifer Schenfeld 2, Benoit Cadieux 3, David Henry 4, Vitor Jose De Sousa Barbosa 3, Hossam Saad 3 Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients with Bone Metastases , American Journal of Clinical Oncology: 2024
David Henry A commentary on: Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC , Practiceupdate: 2024
David Henry A commentary on: Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA , PracticeUpdate: 2024
